Physician profile
Ali Alamar
NPI 1972606374
$4,905.55
in general payments reported to CMS, 2019-2025
30 companies · $652 in 2025
The $652 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $749 · 2020: $133 · 2021: $440 · 2022: $2,047 · 2023: $491 · 2024: $394 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,536.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $1,578.82 | 2022 | |
| Lilly USA, LLC | $923.58 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $459.97 | 2019-2025 | Spravato |
| Boston Scientific Corporation | $304.29 | 2023-2025 | Watchman Access System, Watchman Flx, Wavewriter Alpha Prime 16 |
| Astrazeneca Pharmaceuticals LP | $171.92 | 2022-2025 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $165.04 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $143.82 | 2024-2025 | Rexulti |
| Ucb, INC. | $124.43 | 2024 | Briviact |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.26 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $112.58 | 2023 | Aptiom |
| Glaxosmithkline, LLC. | $107.15 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.87 | 2023-2025 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $93.06 | 2019 | |
| Pfizer INC. | $66.44 | 2024 | |
| Ironwood Pharmaceuticals, INC | $55.71 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $44.46 | 2024 | |
| Abbott Laboratories | $42.66 | 2019 | |
| Gilead Sciences, INC. | $34.16 | 2025 | |
| Paratek Pharmaceuticals, INC. | $31.77 | 2025 | Nuzyra |
| Ultragenyx Pharmaceutical INC. | $29.93 | 2022 | |
| Astellas Pharma US INC | $29.52 | 2025 | Veozah |
| Lundbeck LLC | $29.43 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $20.91 | 2019 | |
| Azurity Pharmaceuticals, INC. | $19.88 | 2025 | Alvesco |
| Teva Pharmaceuticals USA, INC. | $19.80 | 2025 | Austedo Xr |
| Allergan, INC. | $18.96 | 2019 | |
| Mylan Specialty L.P. | $17.35 | 2019 | |
| Horizon Therapeutics Plc | $15.80 | 2020 | |
| Exact Sciences Corporation | $14.36 | 2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Alamar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.